Skip to content
Head to head

Syndax Pharmaceuticals vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: SNDX · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

SNDX -49.2%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
SNDXVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price8.72515.02
Change today-4.49%-1.08%
1-year return-48.9%+22.0%
Market cap$785.05M$130.58B
52-week range8.41 – 25.59412.27 – 568.67
Valuation
P/E (TTM)-3.6833.14
P/E percentile, own 5-yr range66th99th
P/B-45.656.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-3.2915.32
Net profit (TTM)$-296.19M$3.88B
Revenue (TTM)$289.68M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+81.6%+11.8%
Gross margin92.2%85.5%
Operating margin-61.7%33.1%
Net margin-72.3%30.7%
Free cash flow (TTM)$-177.46M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership119.8%96.8%
Insider activity (12mo)25 buy / 23 sell28 buy / 22 sell
Short interest (% of float)21.2%1.9%
Analyst consensus83% buy / 17% hold (6)95% buy / 5% hold (21)
Analyst price target$38 (+332%)$624 (+21%)
StockVane view
StockVane Quant RatingE (7)C (68)
Company
Employees2776,400
Founded20051989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.